Drugs / BMS-986224
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03634969 | Aug 2018 → Apr 2019 | heart failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03563950 | Jun → Jul 2018 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03281122 | Sep 2017 → Apr 2019 | heart failure | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986224 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03281122 ↗ |
| Modality | Small molecule | — CHEMBL4873876 ↗ |
| Route | Oral | “Oral administration” NCT03563950 ↗ |